Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


14th Asia Pacific Oncologists Annual Meeting

Melbourne, Australia

Qiong Ma

Qiong Ma

Fourth Military Medical University, China

Title: A therapeutic target for chemo-resistance in human osteosarcoma


Biography: Qiong Ma


The combination of aggressive surgery and neoadjuvant chemotherapy is also the major treatment for human osteosarcoma nowadays. However, the issue of chemo-resistance development has sustained and poses a great challenge. Researchers have reported that hypoxia may lead to drug resistance in many kinds of solid tumors. The mechanism is not very clear yet. The purpose of this study is to explore how hypoxia leading to chemo-resistance in osteosarcoma cells. We scanned normoxia and hypoxia cultured osteosarcoma cells in silico in three replicates to find the differential expressed gene under hypoxic condition, and this gene was overexpressed by lenti-virus vector, then real-time PCR and western were utilized to detect the expression of three drug resistance related genes ABCB1, ABCC2, and GSTP1. Cell Counting Kit-8 (CCK8) assay was performed to evaluate the proliferation of cells after lenti-virus transfected. 545 differentially expressed genes were identified based on the microarray analysis. Attention was focused on the SKA1 gene as a possible downstream target of hypoxia by means of bioinformatics. SKA1 overexpression reduced the expression of three multidrug resistant genes ABCB1, ABCC2 and GSTP1. Also, we demonstrated that SKA1 overexpression enhanced the sensitivity of two chemotherapeutic drugs used for osteosarcoma patients. Our study made an attempt to identify the downstream target genes that are altered in the hypoxia-cultured osteosarcoma cell line by microarray analysis. We demonstrated that the expression of SKA1 was significantly decreased in a hypoxic environment. And SKA1 may function as a chemosensitizer in osteosarcoma. A strategy to enhance its expression may prove to be beneficial for the treatment of osteosarcoma.